High Overweight and Obesity in Fontan Patients: A 20-Year History

Stephanie T Chung1,2, Borah Hong3,4, Lance Patterson3

  • 1Department of Pediatrics, Pediatric Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX, USA. chungst@niddk.nih.gov.

Pediatric Cardiology
|September 18, 2015
PubMed

Insights

Obesity is common in adults with Fontan circulation, with childhood obesity predicting adult weight gain and higher blood pressure. Early weight management is crucial for long-term health in these patients.

Area of Science:

  • Cardiology
  • Pediatrics
  • Public Health

Background:

  • Obesity prevalence is rising in adults with complex congenital heart disease.
  • Little is known about weight gain patterns in high-risk Fontan circulation patients.

Purpose of the Study:

  • To determine overweight/obesity prevalence and body mass index (BMI) changes with age in Fontan circulation survivors.
  • To identify predictors of adult overweight/obesity and its association with heart failure rates.

Main Methods:

  • Longitudinal analysis of BMI in 606 Fontan circulation patients (1992-2012).
  • Stratification of clinic encounters by age groups: 2-5, 6-11, 12-19, and >20 years.
  • Comparison of pediatric overweight/obesity rates with national data (NHANES 2011-2012).

Main Results:

  • 39% of adult Fontan survivors were overweight/obese.
  • Childhood overweight/obesity (BMI ≥ 85th percentile) tripled the likelihood of adult overweight/obesity.
  • Overweight/obesity in adulthood was linked to lower heart failure rates (4% vs. 19%).
  • Pediatric overweight/obesity rates were comparable to national averages.
  • Elevated systolic blood pressure was observed in overweight/obese children as young as 2-5 years.

Conclusions:

  • Fontan circulation survivors exhibit high rates of overweight/obesity in childhood and adulthood.
  • Childhood obesity is a significant predictor of adult adiposity and early changes in blood pressure.
  • Early identification and management of weight are critical for improving long-term outcomes in Fontan patients.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
341
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
384
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
583
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
284
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
430